Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Recursion Pharmaceuticals, Inc., Neurocrine Biosciences or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Recursion Pharmaceuticals, Inc., Neurocrine Biosciences and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Recursion Pharmaceuticals, Inc., Neurocrine Biosciences and Inc.

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer’s disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Latest Biotechnology and Recursion Pharmaceuticals, Inc., Neurocrine Biosciences, Inc. Stock News

As of September 4, 2026, Recursion Pharmaceuticals, Inc. had a $1.9 billion market capitalization, compared to the Biotechnology median of $282.4 million. Recursion Pharmaceuticals, Inc.’s stock is down 11.2% in 2026, up 8.7% in the previous five trading days and down 19.69% in the past year.

Currently, Recursion Pharmaceuticals, Inc. does not have a price-earnings ratio. Recursion Pharmaceuticals, Inc.’s trailing 12-month revenue is $54.9 million with a -945.9% net profit margin. Year-over-year quarterly sales growth most recently was -59.9%. Analysts expect adjusted earnings to reach $-0.923 per share for the current fiscal year. Recursion Pharmaceuticals, Inc. does not currently pay a dividend.

As of September 4, 2026, Neurocrine Biosciences, Inc. had a $15.8 billion market cap, putting it in the 83rd percentile of all stocks. Neurocrine Biosciences, Inc.’s stock is up 9.7% in 2026, up 1% in the previous five trading days and up 10.86% in the past year.

Currently, Neurocrine Biosciences, Inc.’s price-earnings ratio is 22.8. Neurocrine Biosciences, Inc.’s trailing 12-month revenue is $3.4 billion with a 20.9% net profit margin. Year-over-year quarterly sales growth most recently was 39.5%. Analysts expect adjusted earnings to reach $10.197 per share for the current fiscal year. Neurocrine Biosciences, Inc. does not currently pay a dividend.

How We Compare Recursion Pharmaceuticals, Inc., Neurocrine Biosciences and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Recursion Pharmaceuticals, Inc., Neurocrine Biosciences and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Recursion Pharmaceuticals, Inc., Neurocrine Biosciences and Inc.’s Quality Grades

Company	Ticker	Quality
Recursion Pharmaceuticals, Inc.	RXRX	D
Neurocrine Biosciences, Inc.	NBIX	A

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Recursion Pharmaceuticals, Inc. has a Quality Score of 26, which is Weak. Neurocrine Biosciences, Inc. has a Quality Score of 86, which is Very Strong.

The Quality Grade Winner: Neurocrine Biosciences, Inc.

As you can clearly see from the Quality Grade breakdown above, Neurocrine Biosciences, Inc. has a better overall quality grade than Recursion Pharmaceuticals, Inc.. For investors who are looking for companies with higher quality than others in the same industry, Neurocrine Biosciences, Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Recursion Pharmaceuticals, Inc., Neurocrine Biosciences and Inc.’s Momentum Grades

Company	Ticker	Momentum
Recursion Pharmaceuticals, Inc.	RXRX	D
Neurocrine Biosciences, Inc.	NBIX	C

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Recursion Pharmaceuticals, Inc. has a Momentum Score of 31, which is Weak. Neurocrine Biosciences, Inc. has a Momentum Score of 41, which is Average.

The Momentum Stock Winner: No Clear Winner

Neither Recursion Pharmaceuticals, Inc., Neurocrine Biosciences or Inc. has a strong enough Momentum Grade to be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Recursion Pharmaceuticals, Inc., Neurocrine Biosciences or Inc. is the better investment when it comes to momentum.

Recursion Pharmaceuticals, Inc., Neurocrine Biosciences and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Recursion Pharmaceuticals, Inc.	RXRX	D
Neurocrine Biosciences, Inc.	NBIX	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Recursion Pharmaceuticals, Inc. has a Earnings Estimate Score of 32, which is Negative. Neurocrine Biosciences, Inc. has a Earnings Estimate Score of 47, which is Neutral.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Recursion Pharmaceuticals, Inc., Neurocrine Biosciences or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Recursion Pharmaceuticals, Inc., Neurocrine Biosciences or Inc. is the better investment when it comes to estimate revisions.

Other Recursion Pharmaceuticals, Inc., Neurocrine Biosciences and Inc. Grades

In addition to Estimate Revisions, Quality and Momentum, A+ Investor also provides grades for Value and Growth.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Recursion Pharmaceuticals, Inc., Neurocrine Biosciences and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Recursion Pharmaceuticals, Inc., Neurocrine Biosciences or Inc. Stock?

Overall, Recursion Pharmaceuticals, Inc. stock has a Momentum Score of 31, Estimate Revisions Score of 32 and Quality Score of 26.

Neurocrine Biosciences, Inc. stock has a Momentum Score of 41, Estimate Revisions Score of 47 and Quality Score of 86.

Comparing Recursion Pharmaceuticals, Inc., Neurocrine Biosciences and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.